XML Financial’s AbCellera Biologics ABCL Stock Holding History

XML Financial’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$448K	Buy	57,025 +15,000	+36%	+$73.3K	0.03%	304
2026 Q1	$147K	Hold	42,025	–	–	0.01%	410
2025 Q4	$144K	Hold	42,025	–	–	0.01%	432
2025 Q3	$211K	Buy	42,025 +7,525	+22%	+$33.2K	0.02%	364
2025 Q2	$118K	Buy	+34,500	New	+$85.9K	0.01%	366

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

XML Financial's ABCL Position: Q2 2026 in Review

XML Financial increased its AbCellera Biologics (ABCL) stake by 36% in Q2 2026, buying an estimated $73.3K and bringing the position to 57,025 shares worth $448K. The position accounts for 0.03% of the portfolio, ranked #304.

XML Financial first reported a position in ABCL in Q2 2025 and has held it in 5 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

XML Financial held 57,025 shares of AbCellera Biologics worth $448K as of Q2 2026.
XML Financial bought 15,000 AbCellera Biologics shares in Q2 2026, an estimated $73.3K.
AbCellera Biologics made up 0.03% of XML Financial's portfolio in Q2 2026, its #304 holding.
XML Financial first reported a position in AbCellera Biologics in Q2 2025 and has held it in 5 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on XML Financial's 13F filing for Q2 2026, filed 24 Jul 2026.